Dihexyltryptamine
pharmaceutical compound
Dihexyltryptamine (DHT), or N,N-dihexyltryptamine, is a drug of the tryptamine family related to serotonergic psychedelics like dimethyltryptamine (DMT). It is an analogue in the structural series of N,N-dialkylated tryptamines that also includes DMT, diethyltryptamine (DET), dipropyltryptamine (DPT), dibutyltryptamine (DBT), and diamyltryptamine (DAT).
Use and effects
DHT, in contrast to its lower homologues including DMT, DET, DPT, and DBT, was completely inactive in terms of hallucinogenic and other effects at a dose of 1 mg/kg in humans. With regard to the lower homologues, DMT, DET, and DPT are all described as fully effective hallucinogens, whereas DBT was described as producing only slight hallucinogenic effects.
Pharmacology
Pharmacodynamics
The drug is active in the conditioned avoidance test and produces dose-dependent hypolocomotion in rodents similarly to psychedelic tryptamines.
Chemistry
Analogues
Analogues of DHT include diethyltryptamine (DET), dipropyltryptamine (DPT), diisopropyltryptamine (DiPT), diallyltryptamine (DALT), and dibutyltryptamine (DBT), among others.
N-Hexyltryptamine
The N-monohexyl analogue of DHT, N-hexyltryptamine (NHT), has also been described. According to Stephen Szara and Alexander Shulgin, this compound was inactive at a dose of up to 100 mg orally.
History
DHT was first described by Stephen Szára and colleagues in 1961. It was briefly mentioned by Alexander Shulgin in his 1997 book TiHKAL, but does not appear to have been synthesized or evaluated by him.
“Dihexyltryptamine” enters the record as pharmaceutical compound. Crown Archives preserves that source wording while asking what Dihexyltryptamine, pharmaceutical and compound can confirm, complicate or overturn.
Why this record matters
“Dihexyltryptamine” is worth following because a concise public description often conceals a longer documentary argument. Here, Dihexyltryptamine, pharmaceutical and compound provides the most credible route into that argument.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated May 13, 2026. The linked authority identifier is Q134836735. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1961 and 1997.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Dihexyltryptamine”, its source revision and the description used here.
- Expand the search: follow Dihexyltryptamine primary sources, Dihexyltryptamine archive and Dihexyltryptamine research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Dihexyltryptamine”?
- What terminology or title could unlock a more precise catalogue search?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Dihexyltryptamine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.